Validation of Minnesota acute graft-versus-host disease Risk Score.

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Acute graft-versus-host disease (GVHD) is a major complication following allogeneic stem cell transplantation.
• Existing clinical grading criteria for acute GVHD have limitations in predicting treatment response and patient outcomes.
• Accurate risk stratification is crucial for optimizing management strategies in acute GVHD.

Purpose of the Study:

• To validate a novel multicenter-developed acute GVHD Risk Score in a contemporary patient cohort.
• To assess the predictive accuracy of the Minnesota GVHD Risk Score for steroid treatment response, survival, and transplant-related mortality.
• To evaluate the score's utility as a bedside tool for risk stratification in acute GVHD.

Main Methods:

• Retrospective analysis of 355 patients diagnosed with acute GVHD and treated with prednisone at the University of Minnesota (2007-2016).
• Patients were categorized into standard-risk and high-risk groups based on the Minnesota GVHD Risk Score.
• Steroid treatment response was assessed at days 14, 28, and 56; survival and transplant-related mortality were analyzed using regression models.

Main Results:

• Overall response rates to steroid treatment were significantly higher in standard-risk versus high-risk GVHD patients at all assessed time points (day 14, 28, and 56).
• High-risk GVHD patients demonstrated a lower likelihood of response at day 28 and had increased risks of 2-year transplant-related mortality and overall mortality.
• Initial GVHD grade did not significantly impact day 28 response, highlighting the prognostic value of the Minnesota Risk Score.

Conclusions:

• The Minnesota GVHD Risk Score is a validated and valuable bedside tool for accurately stratifying risk in patients with acute GVHD.
• The score effectively predicts response to steroid therapy and transplant-related mortality, outperforming traditional clinical grading.
• Implementing a tailored therapeutic approach based on the Minnesota Risk Score may improve patient outcomes and facilitate clinical trial design for novel GVHD treatments.